Abstract | OBJECTIVE: DESIGN: We measured serum TgAb level and evaluated the disease status in 226 DTC patients who had undergone remnant ablation and showed an undetectable Tg result as assessed by immunoradiometric assay. MEASUREMENTS: Radioligand assay of TgAb was performed. Recurrence was assessed by 131I scan, 18F-fluorodeoxyglucose positron emission tomography, sonography, computed tomography, or by surgical operation. RESULTS: Fifty-one patients (22.6%) of the Tg-undetectable patients showed positive TgAb, and 25 (49.0%) of these were confirmed with recurrence. The recurrence rate of TgAb-positive patients was higher than that of TgAb-negative patients (3.4%; P < 0.0001). During follow-up, 73.1% of the disease-free patients showed spontaneously decreased TgAb levels. A total of 71.4% of patients with recurrent cancer, who showed responses to surgical operation or radio- iodine treatment, also showed a decreased TgAb level. CONCLUSIONS: Persistently elevated TgAb levels appear to serve as a useful marker for recurrent or persistent DTC in patients with undetectable serum Tg results. Thus, the routine measurement of TgAb in such patient populations may be indicated.
|
Authors | J-K Chung, Y J Park, T Y Kim, Y So, S-K Kim, D J Park, D S Lee, M C Lee, B Y Cho |
Journal | Clinical endocrinology
(Clin Endocrinol (Oxf))
Vol. 57
Issue 2
Pg. 215-21
(Aug 2002)
ISSN: 0300-0664 [Print] England |
PMID | 12153600
(Publication Type: Journal Article)
|
Chemical References |
- Autoantibodies
- Biomarkers, Tumor
- Iodine Radioisotopes
- anti-thyroglobulin
- Thyroglobulin
|
Topics |
- Adolescent
- Adult
- Autoantibodies
(blood)
- Biomarkers, Tumor
(blood)
- Combined Modality Therapy
- Female
- Follow-Up Studies
- Humans
- Immunoradiometric Assay
- Iodine Radioisotopes
(therapeutic use)
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(diagnosis)
- Prognosis
- Thyroglobulin
(immunology)
- Thyroid Neoplasms
(blood, radiotherapy, surgery)
- Thyroidectomy
|